Peripheral neurotoxicity of oxaliplatin
Conditions
Interventions
experiment group:Oxaliplatin chemotherapy combined with Danggui Sini granules.
Sponsors
Jiangsu Province Hospital on Integration Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. All the selected cases were in accordance with the diagnostic criteria of colorectal cancer and were confirmed by pathology or cytology with stage II-IV; 2. Karnofsky score above 60; 3. Aged 18-80 years; 4. No severe damage to the center of gravity, liver, kidney or hematopoietic system; 5. Volunteer to participate in clinical research and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. with any grade of peripheral neuropathy; 2. Having received chemotherapy drugs with neurotoxicity in one month, such as cisplatin, taxanes , vinblastine alkaloids or bortezomib; 3. We are receiving carbamazepine, phenytoin sodium, valproate sodium, gabapentin, pregabalin, venlafaxine, norvenlafaxine, minapram, duloxetine, tricyclic antidepressants and other drugs that may have therapeutic or preventive effects on neuropathy; 4. A history of second or third degree atrioventricular block; 5. Participate in any other clinical study of preventing and treating neurotoxicity; 6. There is a family history of hereditary/familial neuropathy; 7. Patients with severe infection; 8. Patients with mental illness; 9. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of peripheral neurotoxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median occurrence time of OIPN;KPS;Number of chemotherapy cycles completed; | — |
Countries
China
Contacts
Public ContactXi Chen
Jiangsu Province Hospital on Integration Chinese and Western Medicine
Outcome results
None listed